Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

Mesenchymal stem/stromal cells (MSCs) are self-renewing and multipotent progenitors, which constitute the main cellular compartment of the bone marrow stroma. Because MSCs have an important role in the pathogenesis of multiple myeloma, it is essential to know if novel drugs target MSCs. Melflufen is...

Full description

Bibliographic Details
Main Authors: Arjen Gebraad, Roope Ohlsbom, Juho J. Miettinen, Promise Emeh, Toni-Karri Pakarinen, Mikko Manninen, Antti Eskelinen, Kirsi Kuismanen, Ana Slipicevic, Fredrik Lehmann, Nina N. Nupponen, Caroline A. Heckman, Susanna Miettinen
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cells
Subjects:
melflufen
melphalan flufenamide
peptide–drug conjugate
mesenchymal stem/stromal cells
multiple myeloma
bone marrow
Online Access:https://www.mdpi.com/2073-4409/11/9/1574

Similar Items

Similar Items